Continuous research and clinical studies

MIRTOGENOL® – A first clinical study was performed with 20 patients (45.8 years) on Mirtogenol® and 18 patients (44.7 years) who received placebo.

Patients high intraocular pressure (24- 26) mmHg, cup to disc ratio was more than 0.5 - ‘Initial/Minimal’ field of vision defects - and were not on medication was taken. Dose was 2 tablets Mirtogenol® a day (80 mg Pycnogenol®, 160 mg Mirtoselect®) and treatment period was 3 months. Results showed that MIRTOGENOL® lowered IOP in 19 of 20 patients, there was no effect on visual acuity, but an increased blood flow velocity in retinal and ciliary arteries (color Doppler imaging) and study was published in peer reviewed medical ophthalmology journal.

Supplementation with Mirtogenol significantly relieves high ocular pressure
Effects of MIRTOGENOL® on ocular blood flow and intraocular hypertension in asymptomatic subjects

A second MIRTOGENOL® clinical study has now been completed, which investigated its effect on IOP at a lower dosage (1 tablet a day) . MIRTOGENOL®  was found to significantly improve IOP and maintain a healthier IOP over the six months investigational period. A significant increase of ocular blood flow was identified after taking MIRTOGENOL® . Its effect on IOP was compared with prescribed medication eye drops containing Latanoprost in a parallel group as well as in combination with Latanoprost in a third group.  MIRTOGENOL® was found to take longer to lower IOP than prescribed medication but is almost as effective as Latanoprost.

MIRTOGENOL® potentiates latanoprost in lowering intraocular pressure and improves ocular blood flow in asymptomatic subjects

©HORPHAG/INDENA 2016These statements have not been evaluated by the Food and Drug Administration.
This product is not intended to diagnose, treat, cure, or prevent any disease.